Safety and Efficacy Study of KX2-391 for Treatment of Bone-Metastatic, Castration-Resistant Prostate Cancer

NCT01074138 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

31

Enrollment

INDUSTRY

Sponsor class

Conditions

Bone-Metastatic, Castration-Resistant Prostate Cancer

Interventions

DRUG: KX2-391

Sponsor

Athenex, Inc.